secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001437749-25-003074
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity expands Phase 2 trial of stenoparib in advanced ovarian cancer; enrollment targets H1 2025
--------------------------------------------------------------------------------

- New Phase 2 protocol focuses on advanced, recurrent, platinum-resistant ovarian cancer patients.
- Trial aims to optimize stenoparib dose and refine DRP patient selection criteria for companion diagnostic.
- Some patients on stenoparib for over 14 months demonstrate durable clinical benefit.
- Enrollment expected to begin first half of 2025, subject to regulatory approval including FDA review.
- Stenoparib is a dual PARP/Wnt inhibitor; trial will investigate Wnt pathway impact to differentiate treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925003074/0001437749-25-003074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925003074/allr20250206_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer